SPECIAL NOTICE
A -- Research Involving Efficacy of Transchromosomic Cattle Derived Anti-Alphavirus Antibody In Support of the Naval Medical Research Center, Silver Spring, MD (SAB)
- Notice Date
- 3/19/2014
- Notice Type
- Special Notice
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of the Navy, Bureau of Medicine and Surgery, NMLC, 693 Neiman Street, FT Detrick, Maryland, 21702-9203, United States
- ZIP Code
- 21702-9203
- Solicitation Number
- N32398TCBOVINE
- Archive Date
- 4/4/2014
- Point of Contact
- N/A,
- E-Mail Address
-
NMLC-Research@med.navy.mil
(NMLC-Research@med.navy.mil)
- Small Business Set-Aside
- N/A
- Description
- The Naval Medical Logistics Command (NMLC) intends to award a sole source contract under the authority of FAR 6.302-1 to Sanford Applied Biosciences (SAB), Sioux Falls, SD, 57104, to provide research and development services in support of a study to determine the feasibility of using Transchromosomic Bovine derived polyvalent human immunoglobin (Tc pAb) as a therapeutic and/or prophylactic agent against Venezuelan equine encephalitis (VEE) in support of Naval Medical Research Center (NMRC), Silver Spring, MD. This acquisition pertains to a particular segment of the study wherein Sanford Applied Biosciences (SAB) research staff has the unique capability and expertise in performing the required tasks involving the preparation and execution of Transchromosomic Bovine (Tc BovineTM) vaccination and post-vaccination serum sampling. The base period of performance will be for 24 months and has an estimated value of $933,042.00 and there will be a 24 month option period with an estimated value of $759,960.00. The total estimated value of the contract including all options is $1,692,138.00. SAB has been identified as the only responsible source that can successfully complete the research requirement. SAB has developed the novel diversitAbTM platform of Transchromosomic cattle (Tc BovineTM) that are capable of producing fully human antibodies (Tc pAb) for use in vaccine/therapeutic development. Market research determined that there is no commercial service or item available that will satisfy the Government requirement and that SAB possesses the unique and proprietary technological capability and expertise needed to successfully accomplish the requirement. As such, SAB is the only source capable of providing the products and expertise needed to perform the required testing for this study. This Notice of Intent is not a request for competitive proposals and no solicitation document exists for this requirement. However, parties interested in responding to this notice will need to submit technical data, including cost, sufficient to determine capability. All capability statements received by the closing date of this synopsis will be considered by the Government. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. All capability statements received by 3:30 PM Eastern Time, 3 April 2014 will be considered by the Government. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to NMLC-Research@med.navy.mil and shall reference "N32389TCBOVINE" in the subject line.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DON/BUMED/N62645/N32398TCBOVINE/listing.html)
- Record
- SN03314467-W 20140321/140319234728-e7e2a113293fbad1fa35601893736190 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |